Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
dT+dC in Adults With TK2 Deficiency
2024-510763-35-00Phase 2Authorised
- Sponsor
- Hospital Universitario 12 de Octubre
- Start
- Jul 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 2'-deoxycytidine and doxribtimine in thymidine kinase 2 deficiency (TK2D), sponsored by Hospital Universitario 12 de Octubre. Primary endpoint: Efficacy of dT+dC in adults with TK2 deficiency. Planned start Jul 2024; status: authorised.
02
Drugs
2'-deoxycytidinedoxribtimine
03
Conditions
thymidine kinase 2 deficiency (TK2D)
Beyond the preview
Go deeper on 2024-510763-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510763-35-00.